Fast-acting and reliable, Avelox® (moxifloxacin hydrochloride), a fluoroquinolone, is a synthetic broad-spectrum antibacterial agent that has been approved for safe and effective treatment of respiratory tract infections (RTIs) in adults 18 years of age and older, including: Acute Sinusitis (AS), Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), and Community-Acquired Pneumonia (CAP). Avelox has a wide spectrum of activity that covers the key common community respiratory pathogens. Avelox® has excellent coverage against Gram-positive cocci while retaining good activity against Gram-negative bacteria and atypical pathogens. In addition, it has good in-vitro activity against anaerobes.